Kothala himbutu is a traditional Ayurvedic medicinal plant used to treat diabetes. We aimed to evaluate the safety of an aqueous extract of Kothala himbutu stem (KTE) in normal mice. The mice were divided into two groups: one was administered KTE and the other distilled water for 3 weeks. During the test period, the groups showed no significant differences in body weight gain or plasma parameters, such as fasting blood glucose level, oral glucose tolerance test, or aspartate transaminase (AST) or alanine transaminase (ALT) activity. DNA microarray analysis revealed that expression of genes of known function, such as those for the stress response, ribosomal proteins, transcription, cell function, the inflammatory/immune response, and metabolism (xenobiotic, glutathione, etc.) remained largely unaffected by KTE. However some genes such as catechol-o-methyltransferase and succinyl-CoA synthetase were regulated by KTE, indicating that KTE is not toxic to normal mice and might be effective as a functional food.
Salacia reticulata (Hippocrateaceae), referred to as Kothala himbutu (KT) in Singhalese, is a woody climber native to Sri Lanka, where it is a well-known traditional medicinal plant. The aqueous extract of the roots and stems of this plant is extensively used in Ayurvedic medicine in India and Sri Lanka in treatment in the initial stages of diabetes. 1, 2) It reduces fasting blood glucose levels in rats and mild type-2 diabetic patients. 3, 4) Controlling the fasting blood glucose level is a critical step in the treatment of type-2 diabetes, but little is known about the mechanism behind this effect.
Previous studies in our laboratory using a diabetic model of KK-Ay mice have revealed the mechanisms by which the aqueous extract of the Kothala himbutu stem (KTE) decreases fasting blood glucose. An active compound in KTE, mangiferin, acts directly on liver cells and downregulates the gluconeogenic pathway by regulating fructose-1,6-bisphosphatase expression, resulting in lowered fasting blood glucose levels in the diabetic patient. 5) The recent concept of functional food, intermediates between food and medicine, has gained considerable attention as a key concept in the global food industry. 6, 7) As a result, many people in the United States, Japan, and other industrialized countries now use plants as functional foods in the form of herbal teas and dietary supplements to prevent disease and maintain good health. KT is available commercially as a dietary supplement for the prevention of diabetes and obesity in countries such as the United States and Japan.
An assessment of the safety of KTE, including tests for oral toxicity and chromosomal aberrations in Sprague-Dawley rats, has been performed. 8) Only limited information is available on the safety of KTE, while no gene expression profile of the effects of KTE in normal mice has been reported yet.
There are various methods, including in vitro and in vivo studies, of evaluating food safety. 9) Nutrigenomics, which utilizes high through-put analysis tools, has emerged as an immensely valuable strategy in nutrition research. 10 ) DNA microarray technology is one such tool useful in the evaluation of the safety of foods and natural products. 11, 12) Hence, we investigated the effects of KTE on gene expression in the liver of normal mice using DNA microarrays carrying approximately 10,000 known mouse genes.
The purpose of this study was to evaluate the safety of KTE consumption by non-diabetic mice with a view to validating its presumed benefits in healthy and prediabetic people for its supposed preventive effect. The safety of KTE consumption in normal C57BL/6J mice was evaluated by examining plasma parameters, includy To whom correspondence should be addressed. Fax: +81-49-271-7240; E-mail: mwada@josai.ac.jp Abbreviations: CYP, cytochrome P450; GST, glutathione S-transferase; KT, Kothala himbutu; KTE, aqueous extract of the stem of Kothala himbutu; KTED, freeze-dried aqueous extract of the stem of Kothala himbutu ing postprandial and fasting blood glucose levels, AST and ALT activities, and the hepatic gene expression profile.
Materials and Methods
Preparation of aqueous extract of KT. Whole stems (excluding leaves and roots) of KT, harvested in Sri Lanka, were purchased from the Ayurveda Kothalahimbutu Association (Tokyo). The plant was identified by Dr. G. A. S. Premakumara, Herbal Technology Section, Industrial Technology Institute (Colombo, Sri Lanka). A voucher specimen of the stems was deposited in our laboratory (Department of Clinical Dietetics and Human Nutrition, Faculty of Pharmaceutical Sciences, Josai University, Japan). The stems were dried and ground to a fine powder. One hundred g of the powder was boiled in 12.5 liters of distilled water for 2 h. The solvent was filtered and centrifuged for 10 min at 3;000 Â g to remove particulate matter. The supernatant was designated KT aqueous extract (KTE). KTE was freeze dried (Freeze Dryer System, Labconco, Kansas City, MO) yielding the KTED (9 g). The yield (w/w) of KTED was about 3.8%. The amount of KTED obtained from KTE was about 0.45 mg of dry matter/ml. Animals and diet. We purchased 12 male 4-week-old C57BL/6J mice from Clea Japan (Tokyo). The mice were housed individually in an environmentally controlled room under constant temperature (25 AE 3 C) and a 12-h light/dark cycle. Experiments were performed on the mice after an acclimatization period of 1 week.
Under standardized conditions, the mice (5 weeks old at that time) were divided into two groups. One group was treated with KTE, and the other (the control) was administered distilled water. The treatment and control groups were given with free access to KTE and distilled water respectively. On an average, the mice in the treatment group consumed approximately 2.3 mg of dry matter/5 ml of KTE per d, whereas those in the control group drank approximately 5 ml of distilled water per d. Both groups were given free access to a standard diet (MF diet, Oriental Yeast, Tokyo) for 3 weeks.
The mice were euthanized by cervical dislocation at the age of 8 weeks after overnight fasting. They were then dissected, and the liver tissue was harvested for total RNA isolation. Animal care was in conformance with ''Standards Relating to the Care and Management of Experimental Animals'' laid down by the Ministry of Education of Japan and the Institutional Animal Care and Use Committee of Josai University.
Fasting blood glucose levels and oral glucose tolerance test. The fasting blood glucose levels of the mice the were examined after fasting them for 10 h. The blood samples were collected from the tail vein. The blood glucose concentration was measured using a Glucocard meter (Arkray, Kyoto).
The oral glucose tolerance test (OGTT) was performed on overnight-fasted mice. The control and KTEtreated mice were administered 200 ml of distilled water and 200 ml of KTE respectively, followed by 2 g/kg of glucose. Blood was collected from the tail vein immediately before and 30, 60, and 120 min after administration of glucose to determine blood glucose levels.
Biochemical analysis of plasma. The plasma concentration of glucose was measured with a Glucose C II test Wako kit (Wako Pure Chemicals, Tokyo). Alanine aminotransferase (ALT, EC1.1.1.27) activity and aspartate aminotransferase (AST, EC2.6.1.1) activity were measured using a Transamilase C-II test Wako kit (Wako Pure Chemicals, Tokyo).
Preparation of RNA. Total RNA was isolated using Trizol reagent (Invitrogen, Tokyo) according to the manufacturer's instructions. It was dissolved in diethyl pyrocarbonate-treated distilled water. The concentration of total RNA was estimated from the absorbance at 260 nm. RNAs from the liver tissue were used for DNA microarray analysis.
DNA microarray analysis. All experiments and analyses were performed according to the protocol in the GeneChip Expression Analysis Technical Manual (Affymetrix). Equal amounts of total RNA from six mice in each group were pooled. The mRNAs were reverse-transcribed with T7-(dT) 24 primer and copied into double-strand cDNAs (Superscript Choice System, Invitrogen). Biotin-labeled cRNAs were synthesized (High Yield RNA Transcript Labeling Kit, Affymetrix) and fragmented by heating at 94 C for 35 min. Fragmented cRNAs were hybridized with a GeneChip Murine Genome U74A Array (Affymetrix) according to the Affymetrix protocol. After hybridization and subsequent washing and staining using Affymetrix Fluidics Station 400, the arrays were scanned using an Affymetrix array scanner, and the fluorescence intensity was measured using Microarray Suite 5.0 (Affymetrix).
Statistical analysis. Data were expressed as means AE standard deviation (SD). Treatment effects were analyzed by the Student's t-test. Differences with P < 0:05 were considered statistically significant. Expression analysis systemic explorer (EASE) analysis 13) was carried out using the Database for Annotation, Visualization, and Integrated Discovery (DAVID).
14)

Results
Body weight gain, liver weight, fasting blood glucose levels, and plasma parameters Food intake during the 3-week experimental period did not differ significantly between the two groups. The body weights of the mice in both groups increased steadily during the experimental period. At the end of study, there was no significant difference between the body weight gains of the KTE-treated mice and the control mice. The liver weight (g/100 g of body weight) did not significantly differ between the two groups. As compared to the control mice, the KTE-treated mice tended to have decreased fasting blood glucose levels and plasma glucose concentrations, but the differences between the groups were not significant. Moreover, there were no significant differences in aspartate aminotransferase (AST) activity or alanine aminotransferase (ALT) activity between the KTE-treated and the control mice (Table 1) .
Oral glucose tolerance test
The influence of KTE on postprandial blood glucose levels was examined in glucose-loaded mice. There was no significant difference in the postprandial blood glucose levels between the KTE-treated and the control mice ( Fig. 1 ).
DNA microarray analysis of liver tissue of KTEtreated mice
Changes in gene expression profiles in the liver cells of the treatment and control groups were investigated by DNA microarrays (Table 2) . A total of 5,808 genes were identified as present in both groups by Microarray Suite 5.0 (Affymetrix) on the basis of expression profiles. These genes were then classified into 10 groups on the basis of their known biological functions: transcription (818), cell function (705), inflammatory/immune response (110), metabolism (1403), angiogenesis (59), transport (814), stress response (39), ribosomal proteins (34), and other (522). Genes to which a function could not be ascribed were classified as unknown (1,363). We found that 207 genes were upregulated (n ¼ 194) or downregulated (n ¼ 13) by 2-fold or more in the KTEtreated mice as compared with the control mice. The EASE score (a Fisher Exact Statistic) was used to indicate the probability that a set of genes was present by sampling of annotated genes on the GeneChip Murine Genome U74A Array. Analysis of EASE score was carried out using web-accessible tools available in DAVID on the National Institute of Allergy and Infectious Disease (NIAID) website, as described previously. 13, 14) The EASE scores of all categories were determined to be greater than 0.05 (Table 2) .
CYP51, CYP2C70, and CYP2A5 were upregulated and CYP 7B1 was downregulated by KTE. Additionally, glutachione S-transferases (GSTA2, GSTA4, GSTT1, GSTM2, GSTM5, and GSTM6) were also upregulated by KTE (Table 2) . Moreover, the genes for some enzymes involved in the energy metabolic process exhibited changes in expression: catechol-o-methyltransferase and monoamine oxidase A (the enzyme that degrades catecholamines), and succinyl-CoA synthetase and 3-hydroxy-3-methylglutaryl-CoA reductase were upregulated, and acyl-CoA synthetase medium-chain family member 3 was downregulated by KTE (Table 2) .
Discussion
The metabolic syndrome, comprising obesity, insulin resistance, and dyslipidemia, has become a worldwide epidemic of type-2 insulin-resistant diabetes mellitus. 15) KTE is used as an Ayurvedic dietary supplement in United States and Japan for the prevention of metabolic syndrome, especially diabetes. In this study, we focused on evaluating the safety of KTE consumption in nondiabetic mice, with a view to validating its presumed benefits to healthy people consuming KTE as a functional food.
There was no significant difference in food intake or body weight gain between the KTE-treated and the control mice during the experimental period. The values OGTT was performed on C57BL/6J mice administered KTE or distilled water for drinking for 4 weeks. After 16 h of fasting, glucose (2 g/kg) was administered orally. Before the administration of glucose, the control mice were administered 200 ml of distilled water, and the KTE treated mice were administered 200 ml of KTE. Blood samples were collected before and at 30, 60, and 120 min after glucose administration. Each point represents the mean AE SD (n ¼ 6{8). for liver weight and plasma parameters such as fasting and postprandial blood glucose levels and AST and ALT activities did not differ significantly between the two groups. Although KTE reduced the fasting blood glucose level in the type-2 diabetic model, 5) it did not reduce the fasting or the postprandial blood glucose level in normal mice.
DNA microarray analysis revealed that the expression of genes of known function, such as those for stress response, ribosomal proteins, transcription, cell function, the inflammatory/immune response, angiogenesis, transport, and metabolism (xenobiotic, glutathione, carbohydrate, lipid, catecholamine, etc.) remained largely unaffected by KTE. EASE analysis indicated that KTE did not have any selective effects on the expression of the genes associated with the above categories. Furthermore, the expression of oncogenes (alk, cyclin D1, erbA/ear, erB, fos, jun, myc, ras, and src) and antioncogenes (p16, p53, p107/p130, rb, and wt1) also was not modulated by KTE (data not shown).
The drug metabolism system comprises phase I and II enzymes. Phase I enzymes, mainly CYPs, detoxify a variety of endogenous and exogenous chemicals and activate many carcinogens.
16) The major CYPs involved in drug metabolism in the human body are hCYP1A2, hCYP2C9, hCYP2C19, hCYP2D6, hCYP2E1, and hCYP3A4. 17) Although there are more than 50 CYPs, 90% of drugs are metabolized by just six of these, the two most significant enzymes being hCYP3A4 and hCYP2D6, 18) but KTE upregulates the expression of mCYP2C70, whose human ortholog is hCYP2C9. In humans, hCYP2C9 is the rate-limiting enzyme in the metabolic clearance of clinically used drugs such as the hypoglycemic agents tolbutamide and glipizine, the anticonvulsant phenytoin, and the S-enantiomer of the anticoagulant warfarin. 19, 20) KTE can influence the effects of these drugs, but it remains to be seen whether the changes in CYP2C70 mRNA expression induced by KTE are reflected as alterations in drug metabolism, since the induction level of the mRNA was not very high (2-to 5-fold). Further studies are necessary to determine the exact function of mCYP2C70 in mice.
Phase II enzyme systems catalyze the conjugation of phase I metabolites to various water-soluble molecules such as glutathione or glucronic acid, thereby accelerating the metabolic excretion rate. Glutathione S-transferase (GST) is one of the most important phase II enzymes. In the present study, KTE slightly induced GSTs, suggesting that it modulated the drug-metabolizing capacity of the mice.
It has been reported that some functional foods, such as comfrey (Symphytum officinale), noni (Morinda citrifolia), and black cohosh (Cimicifuga racemosa), are hepatotoxic in experimental animals and humans. [21] [22] [23] [24] Using DNA microarray analysis, Mei et al. founds that comfrey drastically regulates many CYP genes (e.g., CYP2A12, CYP4A12, CYP7A1, CYP2C12, and CYP26), GST genes (Gsta3, Gstm3, and Gstp1), ATP-binding cassette transporters (e.g., Abcb9 and Abcc3), and other metabolism-associated genes in the rat liver. 21) Although KTE altered the mRNA levels of drug-metabolizing enzymes by 2-to 5-fold in our study, comfrey was found to change them by as much as 20-to 100-fold. 21, 22) In this study, there were no significant differences in AST or ALT activities between the KTE-treated and the control mice. Furthermore, hepatoprotective and antioxidative effects have been reported for hot-water extracts of the roots and stems of KT in liver injury model mice. 25) Although KTE induced gene expression of some drug-metabolizing enzymes, it is probably not hepatotoxic in normal mice.
An anti-obesity effect has been reported for the aqueous extract of the roots of KT in Zucker fatty. 26) There are, however, only a few reports on the effect of KT consumption in normal mice. Kishino et al. have reported an antiobesity effect of a mixture of Salacia reticulata extract and cyclodextrin in normal C57BL/6J mice fed a high-fat diet.
27) The mechanisms of the antiobesity effect of KTE in normal mice has not yet been reported.
In this study, we used DNA microarray analysis and found that KTE regulated the mRNA level of genes related to energy metabolism, such as catechol-omethyltransferase, monoamine oxidase A, succinylCoA synthetase, 3-hydroxy-3-methylglutaryl-CoA reductase, and acyl-CoA synthetase medium-chain family member 3. This data suggests that KTE influences energy metabolism through gene regulation. Further research to clarify the mechanism of gene regulation by KTE is planned.
This study indicates that KTE has no significant acute hepatotoxicity. In conclusion, normal mice can safely consume KTE, and it might be effective as a functional food to maintain good health.
